MYOM3 and Menkes disease: In this context, two fragments of the myofibrillar structural protein myomesin-3 were identified to be abnormally increased in the serum of MD patients (DMD and limb-girdle MD type 2D) using a comprehensive high-resolution MS-based approach, and they are thus proposed as biomarkers for assessing experimental therapies for MD and other neuromuscular disorders [53].